Abstract
Purpose
To evaluate whether intraprocedural 3D quantification of Lipiodol deposition on cone-beam computed tomography (CBCT) can predict tumor response on follow-up contrast-enhanced magnetic resonance imaging (CE-MRI) in patients with hepatocellular carcinoma (HCC) treated with conventional transarterial chemoembolization (cTACE).
Materials and Methods
This IRB approved, retrospective analysis included 36 patients with 51 HCC target lesions, who underwent cTACE with CBCT. CE-MRI was acquired at baseline and 1 month after cTACE. Overall tumor volumes as well as intratumoral Lipiodol volumes on CBCT were measured and compared with the overall and necrotic (non-enhancing) tumor volumes on CE-MRI using the paired student’s t test. Tumor response on CE-MRI was assessed using modified response evaluation criteria in solid tumors (mRECIST). A linear regression model was used to correlate tumor volumes, Lipiodol volumes, and the percentage of Lipiodol deposition on CBCT with the corresponding parameters on CE-MRI. Nonparametric spearman rank-order correlation and trend test were used to correlate the percentage of Lipiodol deposition in the tumor with tumor response.
Result
A strong correlation between overall tumor volumes on CBCT and CE-MRI was observed (R 2 = 0.986). In addition, a strong correlation was obtained between the volume of Lipiodol deposition on CBCT and tumor necrosis (in cm3) on CE-MRI (R 2 = 0.960), and between the percentage of Lipiodol deposition and tumor necrosis (R 2 = 0.979). Importantly, the extent of Lipiodol deposition (in percentage of total tumor volume) correlated strongly with tumor response on CE-MRI (Spearman rho = 0.84, p < 0.001).
Conclusions
Intraprocedural 3D quantification of Lipiodol deposition on CBCT can be used to predict tumor response on follow-up CE-MRI.
Similar content being viewed by others
References
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9. doi:10.1016/S0140-6736(02)08649-X.
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71. doi:10.1053/jhep.2002.33156.
Herber S, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Interv Radiol. 2008;31(4):768–77. doi:10.1007/s00270-007-9270-8.
Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol. 2001;176(3):681–8. doi:10.2214/ajr.176.3.1760681.
Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, et al. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology. 2013;266(2):636–48. doi:10.1148/radiol.12112316.
Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, et al. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol. 2012;47(3):343–6. doi:10.1007/s00535-011-0511-x.
Kim HY, Park JW, Joo J, Jung SJ, An S, Woo SM, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(6):1051–6. doi:10.1111/j.1440-1746.2011.06963.x.
Monsky WL, Kim I, Loh S, Li CS, Greasby TA, Deutsch LS, et al. Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. AJR Am J Roentgenol. 2010;195(5):1220–30. doi:10.2214/AJR.09.3964.
Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(22):4459–65.
El Khaddari S, Gaudin JL, Abidi H, Picaud G, Rode A, Souquet JC. Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session. Gastroenterol Clin Biol. 2002;26(8–9):728–34.
Oh JS, Chun HJ, Choi BG, Lee HG. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vascu Interv Radiol JVIR. 2013;24(4):483–9. doi:10.1016/j.jvir.2013.01.001.
Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, et al. Radiological response predicts survival following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35(11):1343–50.
Tacher V, Radaelli A, Lin M, Geschwind J-F. How I do it: cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320–34.
Loffroy R, Lin M, Rao P, Bhagat N, Noordhoek N, Radaelli A, et al. Comparing the detectability of hepatocellular carcinoma by C-arm dual-phase cone-beam computed tomography during hepatic arteriography with conventional contrast-enhanced magnetic resonance imaging. Cardiovasc Interv Radiol. 2012;35(1):97–104. doi:10.1007/s00270-011-0118-x.
Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, et al. Three-dimensional evaluation of lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol. 2014;21(3):393–9. doi:10.1016/j.acra.2013.11.006.
Chen R, Geschwind JF, Wang Z, Tacher V, Lin M. Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT. J Vascu Interv Radiol : JVIR. 2013;24(12):1837–44. doi:10.1016/j.jvir.2013.08.017.
Tacher V, Lin M, Chao M, Gjesteby L, Bhagat N, Mahammedi A, et al. Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol. 2013;20(4):446–52. doi:10.1016/j.acra.2012.11.009.
Pellerin O, Lin M, Bhagat N, Ardon R, Mory B, Geschwind JF. Comparison of semi-automatic volumetric VX2 hepatic tumor segmentation from cone beam CT and multi-detector CT with histology in rabbit models. Acad Radiol. 2013;20(1):115–21. doi:10.1016/j.acra.2012.07.011.
Lin M, Pellerin O, Bhagat N, Rao PP, Loffroy R, Ardon R, et al. Quantitative and volumetric European association for the study of the liver and response evaluation criteria in solid tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vascu Interve Radiol : JVIR. 2012;23(12):1629–37. doi:10.1016/j.jvir.2012.08.028.
Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, et al. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014;273(3):746–58.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132.
Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012;265(1):115–23. doi:10.1148/radiol.12112264.
Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(2):526–35. doi:10.1053/j.gastro.2011.04.054.
Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind J-F. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Rev Anticancer Ther. 2014;15(2):199–205.
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16. doi:10.1016/j.jhep.2011.03.007.
Guo Y, Yaghmai V, Salem R, Lewandowski RJ, Nikolaidis P, Larson AC, et al. Imaging tumor response following liver-directed intra-arterial therapy. Abdom Imaging. 2013;38(6):1286–99. doi:10.1007/s00261-013-0017-5 PMID: WOS:000328076000014.
Chung JC, Naik NK, Lewandowski R, Deng J, Mulcahy MF, Kulik LM, et al. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroentero. 2010;16(25):3161–7. doi:10.3748/wjg.v16.i25.3161 PMID: WOS:000279765300008.
Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P. Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol. 2009;19(7):1809–16. doi:10.1007/s00330-009-1327-4.
Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, et al. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268(2):431–9. doi:10.1148/radiol.13121637.
Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology. 2002;225(2):416–9. doi:10.1148/radiol.2252011604.
Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, et al. Uveal melanoma metastatic to the liver: the role of quantitative volumetric contrast-enhanced MR imaging in the assessment of early tumor response after transarterial chemoembolization. Transl Oncol. 2014;7(4):447–55. doi:10.1016/j.tranon.2014.05.004.
Jeon UB, Lee JW, Choo KS, Kim CW, Kim S, Lee TH, et al. Iodized oil uptake assessment with cone-beam CT in chemoembolization of small hepatocellular carcinomas. World J Gastroenterol : WJG. 2009;15(46):5833–7.
Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol. 2012;81(12):3985–92. doi:10.1016/j.ejrad.2012.08.012.
Kim S, Yoshizumi TT, Toncheva G, Yoo S, Yin FF. Comparison of radiation doses between cone beam CT and multi detector CT: TLD measurements. Radiat Prot Dosim. 2008;132(3):339–45. doi:10.1093/rpd/ncn305.
Taguchi K, Funama Y, Zhang M, Fishman EK, Geschwind JF. Quantitative measurement of iodine concentration in the liver using abdominal C-arm computed tomography. Acad Radiol. 2009;16(2):200–8. doi:10.1016/j.acra.2008.08.002.
Conflict of interest
MingDe Lin and Alessandro Radaelli are Philips employees. Jean-François Geschwind is a grant recipient of Philips. The control of the data and the information submitted for publication were maintained by the remaining authors (Zhijun Wang, Rongxin Chen, Rafael Duran, Yan Zhao, Gayane Yenokyan, Julius Chapiro, Rüdiger Schernthaner), who had no conflicts of interest.
Statement of Informed Consent
Statement of informed consent was obtained from all individual participants included in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Z., Chen, R., Duran, R. et al. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 38, 1548–1556 (2015). https://doi.org/10.1007/s00270-015-1129-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-015-1129-9